Ranbaxy Reported To Be Seeking Sale Of Biovel Vaccine-Making Unit
This article was originally published in PharmAsia News
Executive Summary
Sources report Ranbaxy Laboratories is attempting to get out of the vaccine-making business, with plans to sell its Biovel unit because of financial losses it has incurred during its three-year ownership of the firm.